A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy.

Date publication

octobre 2020

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BIBEAU Frédéric

Tous les auteurs :
El Sissy C, Kirilovsky A, Van den Eynde M, Muşină AM, Anitei MG, Romero A, Marliot F, Junca A, Doyen J, Mlecnik B, Haicheur N, Fredriksen T, Lagorce C, Jouret-Mourin A, Leonard D, Bibeau F, Iseas S, Roca EL, Cabanne AM, Vaccaro CA, Santino JP, Huertas E, Tougeron D, Carvalho C, Figueiredo N, Perez RO, Habr-Gama A, Scripcariu V, Gerard JP, Galon J, Zeitoun G, Pagès F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32669377

Résumé

No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed in LARC whether a diagnostic biopsy-adapted immunoscore (IS) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy ("Watch-and-Wait").

Mots clés

Aged, Biopsy, CD3 Complex, immunology, CD8-Positive T-Lymphocytes, immunology, Cell Lineage, immunology, Cell Proliferation, drug effects, Disease-Free Survival, Female, Fluorouracil, administration & dosage, Humans, Immunity, drug effects, Male, Middle Aged, Neoadjuvant Therapy, adverse effects, Neoplasm Recurrence, Local, diagnostic imaging, Patient Selection, Rectal Neoplasms, diagnostic imaging

Référence

Clin Cancer Res. 2020 10 1;26(19):5198-5207